Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2018-07-03 Proxy Solicitation & In…
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
PRE 14C
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement filed with the SEC, which is used to provide information to shareholders about corporate actions taken without a meeting, typically by written consent. The text describes an Information Statement regarding an amendment to the Articles of Incorporation to increase authorized shares, approved by written consent of stockholders, and explicitly states that no proxy is being solicited. It includes detailed information about the corporate action, shareholder approval, and related securities transactions. This type of filing is an Information Statement under SEC rules, which corresponds to a Proxy Solicitation & Information Statement (PSI) filing category. It is not a full annual or quarterly report, nor an earnings release or management report. It is not a report publication announcement or a regulatory filing fallback, as it contains substantive information for shareholders. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). Confidence is high given the clear SEC form type and content.
2018-07-03 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 2, 2018. It details a Securities Purchase Agreement involving the issuance of Series A Convertible Preferred Stock and warrants, appointment of a new CEO and board member, and amendments to employment agreements. The content focuses on capital raising activities, issuance of securities, and management changes. The primary focus is on financing activities and changes in capital structure, as well as management appointments. Given the detailed description of the securities purchase and related financing terms, this document fits best under Capital/Financing Update (CAP). Although it also includes management changes, the main emphasis is on the financing transaction. The document is lengthy and contains substantive details, not merely an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2018-07-03 English
CURRENT REPORT AMENDMENT NO.1
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a Current Report filed with the SEC. It specifically expands upon the description of a promissory note entered into by the company, detailing the terms of the note and related warrants. The content focuses on a financing event (creation of a direct financial obligation) rather than a full financial report or earnings release. The document length is short (3452 characters) and it is an SEC filing related to financing activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-05-30 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'CURRENT REPORT' and dated May 21, 2018. It reports the creation of a direct financial obligation through a demand promissory note of $250,000. The content focuses on a financing event involving debt issuance and potential conversion into warrants. The document length is 2637 characters, which is relatively short and primarily announces a financing transaction rather than providing detailed financial statements or analysis. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2018-05-25 English
FORM 10-Q FOR PERIOD ENDED MARCH 31, 2018
Interim / Quarterly Report 9M 2018
2018-05-14 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'CURRENT REPORT' and dated April 25, 2018. It reports the creation of a direct financial obligation, specifically a short-term convertible loan of $100,000 from a board member to the company. The content focuses on a financing event rather than a full financial report, earnings release, or management discussion. The document length is 2899 characters, which is relatively short and consistent with an 8-K filing announcing a specific event. The key event is a financing activity involving a convertible loan, which fits the category of Capital/Financing Update (CAP). Therefore, the appropriate classification is CAP with high confidence.
2018-04-30 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.